Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
JS Smolen, A Beaulieu, A Rubbert-Roth… - The Lancet, 2008 - thelancet.com
Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
JS Smolen, A Beaulieu… - Lancet (London …, 2008 - pubmed.ncbi.nlm.nih.gov
Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
JS Smolen, A Beaulieu, A Rubbert-Roth… - Lancet (London …, 2008 - europepmc.org
Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
JS Smolen, A Beaulieu, A Rubbert Roth… - 2008 - ricerca.unityfvg.it
Abstract Effect of interleukin-6 receptor inhibition with tocilizumab in patients with
rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial …
rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
JS Smolen, A Beaulieu, A Rubbert-Roth… - The Lancet, 2008 - Elsevier
BACKGROUND: Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its
broad effects on immune and inflammatory responses. Our aim was to assess the …
broad effects on immune and inflammatory responses. Our aim was to assess the …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
JS Smolen, A Beaulieu, A Rubbert-Roth… - The Lancet, 2008 - thelancet.com
Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
JS Smolen, A Beaulieu, A Rubbert-Roth… - The Lancet, 2008 - infona.pl
Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad effects on
immune and inflammatory responses. Our aim was to assess the therapeutic effects of …
immune and inflammatory responses. Our aim was to assess the therapeutic effects of …
[引用][C] Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised …
J Smolen, A Beaulieu, A RUBBERT ROTH… - THE LANCET, 2008 - iris.unipa.it
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis
(OPTION study): a double-blind, placebo-controlled, randomised trial. IRIS IRIS Home Sfoglia …
(OPTION study): a double-blind, placebo-controlled, randomised trial. IRIS IRIS Home Sfoglia …
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
J Smolen, A Beaulieu, A Rubbert Roth… - THE LANCET, 2008 - air.uniud.it
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis
(OPTION study): a double-blind, placebo-controlled, randomised trial. Smolen JS, Beaulieu …
(OPTION study): a double-blind, placebo-controlled, randomised trial. Smolen JS, Beaulieu …
[引用][C] Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised …
T BONGARTZ, JS SMOLEN, A BEAULIEU… - Lancet (British …, 2008 - pascal-francis.inist.fr
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis
(OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary CNRS …
(OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary CNRS …